ANTIMICROBIAL 7-(ALPHA-ACYLAMINO-ALPHA-ARYLACETAMIDO)-3-(SUBSTITUTED METHYL)CEPHALOSPORIN COMPOUNDS, THEIR COMPOSITIONS AND PRODUCTION

Abstract: Antimicrobial 7-(α-acylamino-α-arylacetamido)-3-­ (substituted methyl)cephalosporin compounds are rep­ resented by the formula (I) wherein A is an optionally substituted pyridyl group, R₁ and R₂ are optional substituents and T is a 1-alkylene(carboxy, sulfo or dialkylamino), 1,2,3,4-tetrazole-5-thio group or an optionally substituted N-pyridyl group. The COOH group may form a non-toxic salt. Three condensation processes are provided for syn­ thesis of compound (I) from preexisting cephalosporin com­ pounds. Pharmaceutical compositions contain the compound (I) and a carrier; parenteral administration is preferred. The compositions are effective against gram-positive and gram-­ negative bacteria.

Description: Antimicrobial 7- ( a-acylamino-a-arylacetamido)-3-(substituted methyl)cephalosporin compounds, their compositions and roduction The present invention relates to cephalosporin compounds. More particularly, it pertains to antimicrobial 7-(a-acylamino a-arylacetamido )-3- (substituted methyl) cephalosporin compounds, and their composition and use, and to a process for producing the same. The cephalosposporanic acid nucleus is EMI1.1 Antibiotic derivatives thereof are known including one where the 3-position hears a EMI1.2 group (Cephaloridin), and where the 7-position bears various substituents such as EMI2.1 (Celfalexin, Celfaloglycin). However, the known cephalosporins are not all effective against a wide range of bacteria. We have now found that by modification of the substituent groups, improved cephalosporins can be obtained. The cephalosporin compounds of the present invention are those represented by the general formula: EMI2.2 wherein HO-A- represents a hydroxypyridyl group which may further be substituted with a lower alkyl group, a lower alkoxy group, a lower alkanoyl group, a lower alkoxy carbonyl group, a lower alkylmercapto group, a mercapto group, a hydroxyl group, a lower alkoxymethyl group, a halogen atom, a cyano group, a nitro group, a lower alkylsulfonyl group, an arylsulfonyl group, a sulfamoyl group, a carbamoyl group, an aryloxycarbonylamino group, an acetoacetylamino group, a lower alkylamino group, a lower dialkylamino group, a halogenoalkyl group, an alkenyl group, an aryl group, a cycloalkyl group and a condensed ring (lower) cycloalkylene group; R1 and R2 may be the same or different and each represents a hydrogen atom or a substituent selected from a dialkylamino group, a hydroxyl group, an alkanoyloxy group, a lower alkyl group, a lower alkoxy group, a halogen atom and a hydroxymethyl group; T represents a group of one of the formulae: EMI3.1 where R3 represents a carboxy group or a sulfo group, X represents a straight chain or branched chain alkylene group, R4 and R may be the same or different and each represents a lower alkyl group, and R6 and b may be the same or different and each represents a hydrogen atom, a hydroxy group, a carbamoyl group, a carboxy group or a lower alkyl group; and M is a hydrogen atom, a pharmaceutically acceptable non-toxic cation, or, when T is a group of said formula EMI3.2 wherein R6 and e are as defined above, M may be an anionic charge. The term "lower alkyl" and the like used herein means a group in which the alkyl moiety has up to 4 carbon atom, and the term "lower cycloalkyl" or "lower cycloalkylene" means such group having up to 6 carbon atoms. Preferably the hydroxypyridyl group HO-A- may have a lower alkyl substituent, i.e. that group is of the general formula EMI3.3 where R8 is a hydrogen atom or a lower alkyl group. Preferably in a tetrazole group T of formula (a) or (b), the alkylene group X is a lower alkylene group of up to 4 carbon atoms and a pyridyl group T of formula (c) has a single R6 or R7 substituent which is not a lower alkyl group. The nature of the R3 to R7 substituents can have an important effect on the properties of the compound. The present invention also provides antimicrobial compositions comprising an-antimicrobially effective amount of the cephalosporin compound of the formula (I) or its pharmaceutically acceptable non-toxic salt and a carrier or diluent. It further provides a process for producing the cephalosporin compounds of the formula (I). The compounds of the present invention represented by the formula (I) and non-toxic salts thereof exhibit a strong antimicrobial activity against gram-positive and gramnegative bacteria including various microorganisms to which many of the commerially available cephalosporin type antiobiotics are not effective, for example. Pseudomonas aeruginosa, indole-positive Proteus, Serratia or Enterobacter aerogenes. Further, the compounds of the invention and non-toxic pharmaceutically acceptable salts thereof have good water-solubility and excellent pharmacokinetic properties, such as their increased and prolonged serum level in a living body. Thus, they are useful as antimicrobial agents for preventing and treating various bacterial infections caused by said microorganisms in humans and animals, including poultry and domestic animals, without causing any serious side-effects. For the treatment or prevention of such infectious diseases, the compounds of this invention, either individually or in combination with a pharmaceutically acceptable carrier or diluent, or one or more other active ingredient, e.g. chemotherapeutic agent, can be administered parenterally to a subject. The dosage of the compounds of the formula (I) of this invention will vary with the body weight, age and condition of an individual subject, the kind of bacteria, and the pharmacokinetic properties of the particular compound chosen. Although the particular dosage will be determined by a physician taking these factors into consideration, the compounds of the formula (I) are, in general, most desirably administered parenterally at a dosage of from 5 mg/kg of body weight/day to 150 mg/kg of body weight/day, preferably from 15 mg/kg of body weight/day to 100 mg/kg of body weight/day in a single dose or in multiple doses 2 to 5 times daily. The compound of the invention can comprise from 0.1 to 9996 by weight of any pharmaceutical composition. The compounds of this invention can also be administered orally in compositions such as tablets, capsules or granules, e.g. in admixture with conventional pharmaceutical excipients such as calcium carbonate, lactose, talc, starch, gelatin or magnesium stearate; other compositions can be in the form of suppositories or ointments. For parenteral administration the compounds of this invention may be used in the form of a sterile solution or suspension containing additionally a pharmaceutically acceptable diluent or carrier such as water, saline solution, Ringer's solution, glycerin or polyethylene glycol. These preparations or formulations may also contain suitable auxiliary materials, such as stabilizers, buffer substances, wetting agents, emulsifiers, local anesthetics or salts which regulate the osmotic pressure. The a-carbon atom in the side chain at the 7-position in the formula (I), i.e. a phenylglycine moiety, is an asymmetric center and each compound of this invention can exist in two optical isomers. The present invention includes in its scope these two isomers (D-diastereomer and L-diastereomer) as well as a DL-form, with a preferred compound being a D-form. Examples of said pharmaceutically acceptable non-toxic cation of the compounds of the formula (I) are a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a triethylamine salt, a diethanolamine salt, a morpholine salt, a procaine salt, an L-arginine salt and ah L-lysine salt. With respect to the cephalosporin compounds (I) wherein T represents said pyridinium group of the formula: EMI6.1 wherein R6 and N are as defined above, M may be a hydrogen atom or an anionic charge forming an inner salt or betaine with the pyridinium group as defined above. In the former case, the cephalosporin compounds are in the form of the pyridinium salt such as pyridinium chloride. In the latter case, they may be represented by the formula: EMI7.1 wherein HO-A-, R1, R2, R6 and R7 are as defined above. The cephalosporin compounds of the present invention and the salts thereof can be prepared by reacting a carboxylic acid of the formula (II) HO-A-COOH (11) wherein HO-A- is as defined above, or a reactive derivative thereof, with a compound of the formula (III) EMI7.2 wherein R1, R2 and T are as defined above, or a salt or a derivative of the compound of the formula (III). More particularly, the reaction between the compound of the formula (Il) or a salt or a reactive derivative thereof and the compound of the formula (III) or a salt or a derivative thereof is generally conducted in an inert solvent. Examples of the inert solvents are polar solvents such as dichloromethane, chloroform, acetone, tetrahydrofuran, dioxane, acetonitrile, methyl isobutyl ketone, ethyl alcohol, dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamine or sulforane, non-polar solvents such as benzene, toluene, petroleum ether or n-hexane, or a mixture thereof. The term "reactive derivative of the carboxylic acid represented by the formula (II)" means a reactive derivative of the carboxyl group, for example, an acid halide, an acid anhydride, an acid azolide, an active ester or an acid azide. Examples of the reactive derivatives are mixed acid anhydrides with an acid such as a dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, dialkylphosphorous acid, methanesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g. pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutanoic acid), aromatic carboxylic acid or symmetric acid anhydride; acid azolides with imidazole, a substituted imidazole, dimethylpyrazole, triazole or tetrazole; or active esters such as cyanomethyl ester, methoxymethyl ester, e-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, methanesulfonylphenyl ester, phenylthiophenyl ester, p-nitrophenyl- thio ester, p-cresylthio ester, carboxymethylthio ester, pyranyl ester, pyridyl ester, piperidyl ester or 8-quinolylthio ester; or active esters with N,N'-dimethylhydroxylamine, 1-hydroxy-2(1H)-pyridone, N-hydroxysuccinimide or N-hydroxyphthalimide. When the carboxylic acid of the formula (II) is used in the form of a free carboxylic acid or a salt thereof, the reaction is preferably conducted in the presence of a condensing agent, for example, N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N-morpholinoethylcarbodiimide, N-cyclohexyl N- (4-diethylaminocyclohexyl )-carbodiimide, N,N'diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl N-(3-dimethylaminopropyl)carbodiimide, N ,N' -carbonyldi (2-methylimidazole), pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine, alkoxyacetylene, 1-alkoxy- 1-chloroethylene, trialkyl phosphite, ethyl polyphosphate, isopropyl polyphosphate, phosphorus oxychloride, phosphorus trichloride, thionyl chloride, oxalyl chloride, triphenyl phosphine, 2-ethyl-7-hydroxybenzisoxazolium salt, 2ethyl-5-(m-sulfophenyl)isoxazolium hydroxide inner salt or (chloromethylene)dimethylammonium chloride. In this manner, any amidation agents which have generally been used in the fields of peptide chemistry or penicillin and cephalosporin chemistry can be used in preparing the compounds of the formula (I) in the present invention. A salt of a compound of the formula (III) can be an alkali metal or alkaline earth metal salt such as the sodium, potassium or calcium salt, organic base salt such as the trimethylamine, triethylamine, quinoline or collidine salt, organic sulfonic acid salt such as toluenesulfonic acid, naphthalenesulfonic acid or tetralinsulfonic acid salt; and a derivative of a compound of the formula (III) can be a carboxyl derivative such as one having protected carboxyl groups such as in the form of esterified or amidated carboxyl groups or in the form of acid anhydrides. The protected carboxyl derivatives are those having a group which is capable of easily providing a carboxylic acid group by cleavage after acylation and preferably those providing a free carboxylic acid by, for example, solvolysis, e.g. hydrolysis or alcoholysis in an acidic or weakly alkaline medium, hydrogenolysis, reduction, oxidation, nucleophilic substitution, photoreaction or enzymatic reaction. The above-described protected carboxyl derivatives are those having a protective group for carboxylic acid generally used in the field of peptide chemistry or in the field of penicillin and cephalosporin chemistry such as a silyl ester, an organo-tin ester, a toluenesulfonylethyl ester, a -nitrobenzyl ester, a benzyl ester, a phenacyl ester, a 2-furylmethyl ester, a diphenylmethyl ester, a substituted diphenylmethyl ester, p-methoxybenzyl ester, a trityl ester, a benzoyloxymethyl ester, a lower alkanoyloxymethyl ester, a dimethylmethyleneamino ester, a p-nitrophenyl ester, a methylsulfonylphenyl ester, a methylthiophenyl ester, a t-butyl ester, a 4-picolyl ester, an iodoethyl ester, a trichloroethyl ester, a phthalimidomethyl ester, a 3,4dimethoxy or 3,5-dimethoxybenzyl ester, a 2-nitrobenzyl ester, a 2,2'-dinitrobenzyl ester, an acetyloxycarbonyl group, a trichloroethyl ester, a EMI10.1 group, a -CONH=CHR'group wherein R' is an alkyl or aryl group, or a EMI10.2 group. The above-described derivatives of the compounds of the formula (III) can be used in the form of salts thereof such as the hydrochloride, toluenesulfonate, naphthalenesulfonate or tetralinsulfonate. In the case where the above derivative used is in the form of a silyl ester, the derivative may have another silyl group on other moieties which can be silylated, i.e. hydroxy groups or amino groups. The temperature of the reaction between the carboxylic acid represented by the formula (II) or a reactive derivative thereof and the 7-amino-acylamido-cephalosporin represented by the formula (III) or a salt or derivative thereof is not limited, but is generally lower than 500C. Alternatively, the compounds represented by the formula (I) can be prepared by a known process comprising reacting a a-acylamino-a-arylacetamidecephalosporin represented by the formula (IV) EMI11.1 wherein HO-A-, R1 and R2 are as defined above, with a compound of one of the formulae EMI11.2 wherein R3, R4, R5, R6, R7 and X are as defined above, or a salt thereof. Such aknownprocess is disclosed in Japanese Patent Publications Nos. 12136/71, 2340/71 and 14734/71, Japanese Patent Application (OPI) No. 68593/73 (the term "OPI" as used herein refers to a "published unexamined Japanese patent application"), Journal of Chemical Society, 1965, p. 5015, Belgian Patent 864-459, Journal of Medicinal Chemistry, Vol. 17, p. 1312 (1974) and Journal of Organic Chemisty, Vol. 32, p. 500 (1967). Further, the compounds represented by the formula (I) can also be prepared by reacting the acylaminocarboxylic acid represented by the formula (VI) EMI11.3 wherein A, R1 and R2 are as defined above, or a reactive derivative thereof, with a compound represented by the formula (VII) EMI12.1 wherein T is as defined above, or a derivative thereof. The reaction between the acylaminocarboxylic acid of the formula (VI) or a derivative thereof and the compound of the formula (VII) can be conducted in the same manner as described previously for the reaction between the compound (II) and the compound (III). The present invention is further illustrated by the following illustrative Examples. EXAMPLE 1 Preparation of 7-[D-cx-(4-hydroxy-6-methylpyridine-3- carboxyamido )-a- (4-hydroxyphenyl )acetamido]-3- (1 - carboxymethyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4carboxylic acid 8.8 g of a triethylamine salt of 7-[D-a-(4-hydroxy-6 methylpyridine-3-carboxyamido)-a-(4-hydroxyphenyl)acetamido]- cephalosporanic acid, 2.36 g of sodium bicarbonate and 3.0 g of 1-carboxymethyl-5-mercapto-1H-tetrazole were added to 117 ml of a phosphate buffer solution (pH 6.0), and the resulting mixture was allowed to react at 50 C for 16 hours and then at 600C for 3 hours with stirring. The reaction mixture was allowed to cool to room temperature and adjusted to pH 2.0 with 6N hydrochloric acid. The precipitated crystals were collected by filtration and dried over phosphorus pentoxide under reduced pressure to give 6.35 g of a crude product of the compound named at the head of this Example. The crude product thus-obtained was then subjected to liquid chromatography, and the fractions containing the desired product were collected, concentrated and precipitated with an acid by adjusting the mixture to pH 2.0, to give a purified product. An equimolar amount of sodium bicarbonate was added to the above-purified produce and the mixture was freeze-dried to obtain a monosodium salt of the compound. Melting Point, 2570C (decomposition). IR (KBr): 1760, 1660 cm 1 H1-NMR (90 MHz, d6-DMSO): 6 ppm (pattern number of protons, assignment), 2.27 (s, 3H, CH3), 3.45 (broad, 2H, 2-CH2), 4.17 (broad, 2H, 3-CH2), 4.77 (s, 2H, ¯ N-CH2-COO), 4.90 (d, 1H, 6-CH-), 5.63 (dd, 1H, 7-CH), 5.85 (d, 1H, -CONHCH-CO-), 6.21 (s, 1H, 5-proton on pyridine ring), 6.6, 7.15 (d, 4H, proton on phenyl ring), 8.17 (s, 1H, 2-proton on pyridine ring), 9.17 (d, 1H, -C0NH-), 11.32 (d, -CONH-). EXAMPLE 2 The following compound was prepared according to the procedure as described in Example 1 with appropriate modification of the tetrazole reactant: 7- [D- a- (4-hydroxy-6-methylpyridine-3-carboxyamido )-a- (4-hydroxyphenyl)acetamido]-3-(1-sulfomethyl-1H-tetrazol5-ylthiomethyl)-3-cephem-4-carboxylic acid monosodium salt. Melting Point of 2580C (decomposition). IR (KBr): 1750, 1655 (cm 1 H1 -NMR (90 MHz, d6-DMSO): 6 ppm (pattern, number of protons, assignment), 2.33 (s, 3H, -CH3), 3.0-3.8 (broad, 2-CH2), 4.17 (broad, 2H, 3-CH2-S-), 4.94-4.97 (m, 2H, 6-CH-, N-C¯2-S03-), 5.70 (dd, 1H, 7-CH), 6.05 (d, 1H, -CONH-CH-CONH-), 6.27 (s, 1H, 5-proton on pyridine ring), 6.60 (d, 2H, proton on phenyl ring), 7.15 (d, 2H, proton on phenyl ring), 8.17 (s, 1H, 2-proton on pyridine ring), 9.20 (d, 1H, -CONH-), 11.53 (d, 1H, -CONH-). EXAMPLE 3 The following compound was prepared according to the procedure described in Example 1. 7- ED- a- (4-hydroxy-6-methylpyridine-3-carboxyamido )- a- (4 hydroxyphenyl )acetamido]-3-(1 -carboxyethyl-1H-tetrazol- 5-ylthiomethyl)-3-cephem-4-carboxylic acid. Melting Point, 143-1490C (decomposition). H1-NMR (d6-DMSO, 60 MHz): 6 ppm (pattern, number of protons, assignment), 2.27 (s, 3H, -CH3), 2.93 (t, 2H, N-CH2CH2COOH), 3.62 (broad, 2H, 2-CH2), 4.33 (m,¯ N.-CH2CH2COOH), 4.97 (d, 1H, 6-CH), 5.67 (broad, 2H, -CH-, 7-CH), NH 6.27 (s, 1H, 5-proton on pyridine ring), 6.83 (d, 2H, proton on phenyl ring), 7.27 (d, 2H, proton on phenyl ring), 8.27 (s, 1H, 2-proton on pyridine ring), 9.27 (d, 1H, -CONH-), 11.03 (d, 1H, -CONH-). EXAMPLE 4 The following compound was prepared according to the procedure described in Example 1: 7- [D- a- (4-hydroxy-6-methylpyridine-3-carboxyamido )-a- (4-hydroxyphenyl)acetamido]-3-(1-carboxypropyl-1H-tetrazol- 5-ylthiomethyl)-3-cephem-4-carboxylic acid. Melting Point, 182-1830C (decomposition). H1-NMR (60 MHz, d6-DMSO): 6 ppm (pattern, number of protons, assignment), 1.8-2.4 (m, 7H, -CH3, ¯N-CH2-CH2-), 3.63 (broad, 2H, 2-CH2), 4.30 (broad, 4H, 3-CH2, = N-CH2CH2-CH2COOH), 4.98 (d, 1H, 6-CH-), 5.6-5.9 (m, 2H, -CH-, 7-CH), NHCO- 6.28 (s, 1H, 5-proton on pyridine ring), 6.73 (d, 2H, proton on phenyl ring), 7.27 (d, 2H, proton on phenyl ring), 8.30 (s, 1H, 2-proton on pyridine ring), 9.30 (d, 1H, -CON-), 11.1 (d. 1H, -CONH-). EXAMPLE 5 Preparation of 7-[D-y-(4-hydroxy-6-methylpyridine-3 carboxyamido)-a-(4-hydroxyphenyl)acetamido]-3-(1- dimethylaminoethyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4carboxylic acid 8.14 g of triethylamine salt of 7-[D;a-(4-hydroxy-6-methyl- pyridine-3-carboxyamido )-a- (4-hydroxyphenyl )acetamido] - cephalosporanic acid, 1.75 g of sodium bicarbonate and 3.0 g of 1-dimethylaminoethyl-5-mercapto-1H-tetrazole were added to 109 ml of a phosphate buffer solution (pH 6.0), and the resulting mixture was allowed to react at 500C for 16 hours and then at 600C for 3.5 hours with stirring. The reaction mixture was allowed to cool to room temperature and adjusted to pH 2.0 with 6N hydrochloric acid. The precipitated crystals were filtered and dried over phosphorus pentoxide under reduced pressure to obtain 5.0 g of a crude product of the above named compound. The crude product thus-obtained was then subjected to liquid chromatography, and the fractions containing the desired product were collected, concentrated and precipitated with an acid by adjusting to pH 2.0 to obtain a purified product. An equimolar amount of sodium bicarbonate was added to the above purified product and the mixture was freeze-dried to obtain a sodium salt of the compound. Melting Point, 2520C (decomposition). IR (KBr): 1760, 1660 cm 1 H1 -NMR (90 MHz, d6-DMSO): 6 ppm (pattern, number of protons, assignment), 2.05 (s, 6H, EMI16.1 2.33 (s, 3H, methyl group on pyridine ring) 3-3.8 (overlapping with peak of water, 2-Cfl2, -CH2N ), 4-4.5 (m, N-CH2, 3-CH2S-), 4.93 (d, 1H, 6-CH), 5.68 (dd, 1H, 7-CH), 6.1 (d, 1H, -CONHCH-CO-), 6.25 (s, 1H, 5-proton on pyridine ring),l6.51, 7.08 (d, proton on phenyl 6.51, ring), 8.11 (s, 1H, 2-proton on pyridine ring), 9.13 (broad d, -CONH), 11.63 (broad d, -CONH). EXAMPLE 6 Preparation of 7- [D-a- (4-hydroxy-6-methylpyridine-3- carboxyamido)- -(4-hydroxyphenyl)acetamido]-3-(1- pyridinio)methyl-l-ceehem-4-carboxylate A solution of 2.63 g of a triethylamine salt of 7-[D-a- (4-hydroxy-6-methylpyridine-3-carboxyamido )- a- (4-hydroxy phenyl)acetamido)cephalosporanic acid, 10 g of potassium thiocyanate and 0.481 g of pyridine in 10 ml of water was allowed to react at 580 to 600C for 10 hours with stirring. The reaction mixture was allowed to cool to room temperature, 30 ml of water was added thereto and the insoluble substance formed was removed by filtration. The filtrate was adjusted to pH 2 with 2N hydrochloric acid and, after stirring under ice cooling, the precipitated crystals were filtered and dried on phosphorus pentoxide under reduced pressure to obtain 1.60 g of a crude product of the named compound which was then purified by liquid chromatography. H1-NMR (60 MHz, d6DMSO): 6 ppm (pattern, number of protons, assignment), 2.27 (s, 3H, -CH3), 3.43 (broad, 2H, 2-CH2-), 5.07 (d, 1H, 6-CH-), 5.40-5.97 (m, -CH-, 7-CH-, NH 3-CH2), 6.27 (s, 1H, 5-proton on pyridine ring), 6.70. 7.23 (d, 4H, proton on phenyl ring), 8.18 (m, 2H, 3-proton of pyridinium), 8.27 (s, 1H, 2-proton on pyridine ring), 8.58 (d, 1H, 4-proton of pyridinium), 9.02 (d, 2H, 2-proton of pyridinium), 9.28 (broad d, 1H, -CONH-), 11.02 (broad d, 1H, -CONH). EXAMPLE 7 The following compound was prepared according to the procedure as described in Example 6: 7- [D-a- (4-hydroxy-6-methylpyridine-3-carboxyamido)-a- (4-hydroxyphenyl)acetamido]-3-(3-carboxy-1-pyridinio)methyl-3-cephem-4-carboxylate. H1 -NMR (60 MHz, d6-DMSO): 6 ppm (pattern, number of protons, assignment), 2.25 (s, 3H, -CH3), 3.42 (broad, 2H, 2-CH2), 5.05 (d, 1H, 6-CH-), 5.3-6.0 (broad m, EMI17.1 7-CH-, 3-CH2), 6.27 (s, 1H, 5-proton on pyridine ring), 6.70, 7.23 (m, 4H, proton on phenyl ring), 8.32 (m, 2H, 2-proton on pyridine ring, pyridinio proton), 8.67-9.67 (m, -CONH-, pyridinio proton), 11.07 (broad d, 1H, -CONH-). EXAMPLE 8 The following compound was prepared according to the procedure as described in Example 6: 7-rDL -(4-hydrpxy-6-methylpyridine-3-carboxyamino)- - (4-hydroxyphenyl)acetamido]-3-(4-carbamoyl-1-pyridinio)- methyl-3-cephem-4-carboxylate. H1-NMR (60 MHz, d6-DMSO): 6 ppm (pattern, number of protons, assignment), 2.27 (s, 3H, -CH3), 3.45 (broad, 2H, 2-CH2), 5.10 (d, 1H, 6-CH-), 5.27-6.13 (Broad m, 7-CH, -CH NH 3-CH2), 6.30 (s, 1H, 5-proton on pyridine ring), 6.72, 7.25 (m, 4H, proton on phenyl ring), 8.30 (s, 1H, 2-proton on pyridine ring), 8.50 (d, 3-proton of pyridinio), 11.08 (d, 1H, -CONH). EXAMPLE 9 The following compound was prepared according to the procedure as described in Example 6: 7-tDL -(4-hydroxy-6-methylpyridine-3-carboxyamido)-- (4-hydroxyphenyl)acetamido]-3-(4-carboxy-1-pyridinio) methyl-3- cephem-4- carboxylate. H1-NMR (90 MHz, d6-DMSO): 6 ppm (pattern, number of protons, assignment), 2.30 (s, 3H, -CH3), 3,38 (broad, 2H, 2-CH2), 5.03 (d, 1H, 6-CH), 5.2-6.0 (m, 4H, EMI18.1 7-CH3-CH2), 6.27 (s, 1H, 5-proton on pyridine ring), 6.68, 7.22 (m, 4H, proton on phenyl ring), 8.33 (s, 1H, 2-proton on pyridine ring), 8.43 (d, 2H, 3-proton of pyridinio), 9.25 (d, 2H, 2-proton of pyridinio), 11.08 (d, 1H, -CONH-). Preparation of 7-[D-a-(4-hydroxylpyridine-3-carboxyamido)- -(4-hvdroxyphenyl)acetamido1cephalosporan-ic acid EMI19.1 5 g of 7-[D- -(2-methoxybenzyloxycarbonylamino)- -(ç- hydroxyphenyl)acetamido]cephalosporanic acid was added to a solution comprising 25 ml of trifluoroacetic acid and 2.5 ml of anisol under ice-cooling and stirring, and the mixture was stirred for 15 minutes. Then, the reaction mixture was added dropwise to 500 ml of diethyl ether while stirring. The precipitated crystals were collected by filtration, washed with diethyl ether, and dried over phosphorus pentoxide under reduced pressure to obtain 3.62 g of a trifluoroacetic acid salt of 7-[D-a-amino-a-(E- hydroxyphenyl)acetamido]cephalosporanic acid. Then, 3.45 g of 7-[D-a-amino--(E-hydro:xyphenyl )acetamido)cephalosporanic acid and 1.5? g of 4-hydroxypyridine-3-carboxylic acid N-hydroxysuccinimide ester were added to 21 ml of dimethyl sulfoxide, and 1.95 g of triethylamine was added dropwise thereto at room temperature. After allowing the mixture to react for 40 minutes with stirring, 115 ml of acetone was added to the resulting reaction mixture which was then stirred for one hour. After stirring the mixture for 30 minutes under ice-cooling, the precipitated crystals were collected by filtration, washed with acetone and dried over phosphorus pentoxide under reduced pressure to afford 3.14 g of a triethylamine salt of the named compound. Melting Point, 155-1570C (decomposition). Preparation of 7-[D-cr-(4-hydroxy-6-methylpyridine-3- carboxyamido )- a- (4-hydroxyphenyl )acetamido]-cephalo- sporanic acid 21.96 g of anisol and 70.0 g of -toluenesulfonic acid monohydrate were dissolved in 714 ml of acetonitrile, and 119 g of 7-[D-a-(-methoxybenzyloxycarbonylamino)-a- (E-hydroxyphenyl )acetamido] cephalosporanic acid was added thereto, followed by allowing the mixture to react for 40 minutes with stirring. Thereafter, 238 ml of dimethyl sulfoxide and then 49.2 g of 4-hydroxy-6-methylpyridine3-carboxylic acid N-hydroxysuccinimide ester were added to the reaction mixture at ?OOC, and 82.3g of triethylamine was added dropwise thereto at that temperature. After completion of the addition, the resulting mixture was stirred at the same temperature for 40 minutes and then further allowed to react at 15 C to 20 C for 1 hour with stirring. 2 lox acetone was added dropwise to the reaction mixture- for 10 minutes and the mixture was stirred at 180C for 30 minutes and then under ice-cooling for 1 hour. The crystals precipitated were collected by filtration, washed with 450 ml of acetone and dried over phosphorus pentoxide under reduced pressure to afford 95 g of a triethylamine salt of the named compound. Melting Point, 1 60-1730C (decomposition).

Claims: Claims: in compound of the 1. A 3,7-substituted cephalosporin compound of the general formula: EMI21.1 wherein HO-A represents a hydroxypyridyl group, which may further be substituted with a halogen atom, a hydroxy, cyano, nitro, carbamoyl, mercapto, sulfamoyl or alkenyl group or an alkyl, alkoxy, alkanoyl, alkoxycarbonyl, alkylmercapto, alkoxymethyl, alkylamino, dialkylamino or alkylsulfonyl group in each of which the alkyl moiety has up to 4 carbon atoms, a haloalkyl group, an arylsulfonyl group, an aryloxycarbonylamino group, an acetoacetylamino group, an aryl group or a cycloalkyl group having up to 6 carbon atoms or a condensed ring cycloalkylene group having up to 6 carbon atoms; R1 and R2 each represents a hydrogen or halogen atom or a hydroxy, hydroxymethyl, dialkylamino or alkanoyloxy group or an alkyl or alkoxy group having up to 4 carbon atoms; T represents a group of one of the formulae: EMI21.2 wherein R3 represents a carboxyl or sulfo group, X represents an alkylene group, R4 and R5 each represents an alkyl group of up to 4 carbon atoms, and R6 and R7 each represents a hydrogen atom, a hydroxy group, a carbamoyl group, a carboxy group or an alkyl group of up to 4 carbon atoms; M is a hydrogen atom, a pharmaceutically acceptable nontoxic cation or when T is a group of the aforesaid formula (c) M may be an anionic charge. 2. A compound according to Claim 1, wherein in the hydroxypyridyl group HO-A-, the pyridyl ring is not further substituted or is substituted with an alkyl group. 3. A compound according to Claim 1 or 2, wherein the alkylene group represented by X is of the formula -(CH2)n-, wherein n is an integer of 1 to 4. 4. A compound according to Claim 1 or 2, wherein the group (c) is unsubstituted or R6 or R7 is a carboxyl or carbamoyl group. 5. A D-isomer of a compound as claimed in any of Claims 1 to 4. 6. A pharmaceutically acceptable non-toxic salt of a compound as claimed in any of Claims 1 to 5. 7. A process of producing a compound as claimed in any of Claims 1 to 6, which comprises reacting a compound of the general formula: HO-A- COOH wherein HO-A- is as defined in Claim 1, or a reactive derivative thereof, with a compound of the general formulat EMI23.1 wherein R1, R2, T and M are as defined in Claim 1, or a reactive derivative thereof. 8. A process of producing a compound as claimed in any of Claims 1 to 6, which comprises reacting a compound of the general formula: EMI23.2 wherein HO-A-, R1 and R2 are as efined in Claim 1, or a salt thereof, with a compound of one of the formulae: EMI23.3 wherein R3, R4, R5, R6 and R7 are as defined in Claim 1. 9. A process of producing a compound as claimed in any of Claims 1 to 6, which comprises reacting a compound of the general formula: EMI24.1 wherein HO-A-, R1 and R2 are as defined in Claim 1, or a reactive derivative thereof, with a compound of the formula: EMI24.2 wherein T and M are as defined in Claim 1, or a salt or a derivative thereof. 10. An antimicrobial composition comprising an antimicrobially effective amount of a compound as claimed in any of Claims 1 to 5 or produced by a process as claimed in Claim 7, 8 or 9, and a carrier or diluent.

Inventors: JIMPO, KIYOKAZU, NOGUCHI, HIROSHI, OKUDA, TAKAO, TOBIKI, HISAO, YAMADA, HIROTADA
Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED
Application year: 1981
Main classification: C07D501
IPC codes: A61K31, C07D501